ST

Seshu Tyagarajan

Chief Technical and Development Officer

Candel Therapeutics

Needham, Massachusetts


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Candel Therapeutics
Industry
research
Employees
61.0
Seniority
C suite
Annual Revenue
125000.0

Technologies

Outlook Microsoft Office 365 Amazon AWS WordPress.org Bootstrap Framework BugHerd Google Tag Manager Mobile Friendly Typekit Akamai RUM Vimeo Google Font API Remote SAP Circle

Keywords

immunooncology oncology viral immunotherapy prostate cancer brain cancer biotechnology biotechnology: biological products (no diagnostic substances) health care biotechnology research cancer treatment individualized response adenoviral therapies herpes simplex virus tumor immune response antigen presentation in situ vaccination immune checkpoint inhibitors clinical trials can-2409 can-3110 systemic immune response targeted cancer therapy solid tumors immunogenic cell death pro-inflammatory signaling cd8 t cell activation metastatic cancer tumor microenvironment personalized medicine tumor anti-tumor mechanisms cancer survivability therapeutic innovative design oncolytic virus regulatory approvals immuno-oncology patient quality of life tumor antigens evidence-based science therapeutic pipelines drug development bioengineering genetic engineering cancer innovation immune system education tumor-specific therapies biotech leadership research advisory board resilient oncology solutions monotherapy therapeutic combinations targeted injections clinical research patient outcomes affordable cancer therapies genetically modified constructs hospital & health care health wellness & fitness

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans